| Exclusion Criteria: | 1) Patient has a history of prior treatment with a deacetylase (DAC) inhibitor including panobinostat
2) Patient will need valproic acid for any medical condition during the study or within 5 days prior to the first panobinostat treatment
3) Patient has been treated with monoclonal antibody therapy (e.g., rituximab or anti CD-30 antibody, etc.) within 4 weeks of start of study treatment
4) Patient has received chemotherapy or any investigational drug or undergone major surgery </= 2 weeks prior to starting study drug or whose side effects of such therapy have not resolved to </= grade 1
5) Patient has been treated with > 5 prior systemic lines of treatment
6) Patient has received prior radiation therapy </= 4 weeks or limited field radiotherapy </= 2 weeks prior to start of study treatment or whose side effects of such therapy have not resolved to </= grade 1
7) Patient is using any anti-cancer therapy concomitantly
8) Patient treated with allogeneic hematopoietic stem cell transplant who is currently on or has received immunosuppressive therapy within 90 days prior to start of screening and/or have >/= Grade 2 graft versus host disease (GvHD)
9) Patient has a history of another primary malignancy </= 3 years before study entry, with the exception of non-melanoma skin cancer, and carcinoma in situ of uterine cervix
10) Patient has a history of central nervous system (CNS) involvement with lymphoma
11) Patient has impaired cardiac function including any of the following: Complete left bundle branch block or use of a permanent cardiac pacemaker, congenital long QT syndrome, history or presence of ventricular tachyarrhythmias, clinically significant resting bradycardia (<50 beats per minute), QTcF > 450 msec on screening ECG, or right bundle branch block + left anterior hemiblock (bifascicular block); (Continued in next inclusion)
12) (Continued from previous inclusion) Presence of atrial fibrillation (ventricular heart rate >100 bpm); Previous history angina pectoris or acute MI within 6 months; Congestive heart failure (New York Heart Association functional classification 3/4) or baseline MUGA/Echo shows LVEF < 45%
13) Patient has any other clinically significant heart disease (e.g., uncontrolled hypertension)
14) Patient has an impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, obstruction, or stomach and/or small bowel resection)
15) Patient has unresolved diarrhea >/= grade 2
16) Patient has any other concurrent severe and/or uncontrolled medical condition(s) (e.g., uncontrolled diabetes mellitus, active or uncontrolled infection, chronic obstructive or chronic restrictive pulmonary disease including dyspnoea at rest from any cause) that could cause unacceptable safety risks or compromise compliance with the protocol
17) Patient has a known history of HIV seropositivity (screening HIV testing is not required)
18) Patient is using medications that have a relative risk of prolonging the QT interval or of inducing Torsade de Pointes, where such treatment cannot be discontinued or switched to a different medication prior to starting study drug
19) Patient is a woman who is pregnant or breast feeding, or a women of childbearing potential (WOCBP) not willing to use a double method of contraception during the study through 3 months after the end of treatment. One of these methods of contraception must be a barrier method. WOCBP are defined as sexually mature women who have not undergone a hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive months (i.e., who has had menses any time in the preceding 12 consecutive months). WOCBP must have a negative serum pregnancy test at baseline.
20) Male patient whose sexual partner(s) are WOCBP who are not willing to use a double method of contraception, one of which includes a condom, during the study and for 3 months after the end of treatment
21) Patients with any of the following contraindications to PET are excluded from the [18F]-FDG PET study: Fasting blood glucose above 200 mg/dL, at time of PET scan
22) Inability to lay down for 60 minutes or has a history of claustrophobia
23) Patient not at a participating center |